What Are The Chances Of Ocular Therapeutix Inc (NASDAQ: OCUL) Becoming A Clear Buy?

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

As a NASDAQ listed company, OCUL falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Ocular Therapeutix Inc is $1.22B. A total of 1.29 million shares were traded on the day, compared to an average of 2.14M shares.

In the most recent transaction, ANTONY MATTESSICH bought 23,979 shares of OCUL for 8.19 per share on Aug 01 ’24. In a previous transaction on May 23 ’24, Dugel Pravin sold 21,626 shares at 5.79 per share. OCUL shares that the insider owns now total 833,353.

Among the insiders who sold shares, Nayak Sanjay disposed of 2,274 shares on May 23 ’24 at a per-share price of $5.84. This resulted in the Chief Strategy Officer holding 178,026 shares of OCUL after the transaction. In another insider transaction, SUMMER ROAD LLC bought 930,851 shares at $7.52 per share on Feb 26 ’24. Company shares held by the 10% Owner now total 8,591,401.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, OCUL has a high of $11.31 and a low of $2.00.

As of this writing, OCUL has an earnings estimate of -$0.22 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of -$0.14 per share and a lower estimate of -$0.25.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. OCUL’s latest balance sheet shows that the firm has $164.16M in Cash & Short Term Investments as of fiscal 2021. There were $58.98M in debt and $26.34M in liabilities at the time. Its Book Value Per Share was $2.64, while its Total Shareholder’s Equity was $88.00M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for OCUL is Buy with a score of 4.78.

Most Popular

Related Posts